Literature DB >> 29239282

Generation of Human-Induced Pluripotent Stem Cells from Wolfram Syndrome Type 2 Patients Bearing the c.103 + 1G>A CISD2 Mutation for Disease Modeling.

Alberto La Spada1, Aikaterini Ntai2, Stefano Genovese3, Maurizio Rondinelli3, Pasquale De Blasio2, Ida Biunno1,4.   

Abstract

Wolfram syndrome (WFS) is a rare autosomal premature aging syndrome that shows signs of diabetes mellitus, optic atrophy, and deafness in addition to central nervous system and endocrine complications. The frequent form of WFS type 1 (WFS1) harbors causative mutations in the WFS1 gene, whereas the rare form or WFS type 2 (WFS2) involves CISD2. Mutations in these two genes are recognized by a subset of variable clinical symptoms and a set of overlapping features. In this study, we report on the generation of stable human-induced pluripotent stem cells (hiPSCs) derived from primary fibroblasts of a previously reported Italian family with CISD2 mutation (c.103 + 1G>A), occurring in the consensus intron 1 splicing site in two sisters, deleting the first exon of the transcript. The generated hiPSCs provide a cell model system to study the mutation's role in the multisystemic clinical disorders previously described and test eventual drug effects on the specific and associated clinical phenotype.

Entities:  

Keywords:  Wolfram syndrome type 2; disease modeling; induced pluripotent stem cells

Mesh:

Substances:

Year:  2018        PMID: 29239282     DOI: 10.1089/scd.2017.0158

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  2 in total

Review 1.  Who Will Win: Induced Pluripotent Stem Cells Versus Embryonic Stem Cells for β Cell Replacement and Diabetes Disease Modeling?

Authors:  Elena F Jacobson; Emmanuel S Tzanakakis
Journal:  Curr Diab Rep       Date:  2018-10-20       Impact factor: 4.810

Review 2.  Pluripotent Stem Cell-Based Approaches to Explore and Treat Optic Neuropathies.

Authors:  Oriane Rabesandratana; Olivier Goureau; Gaël Orieux
Journal:  Front Neurosci       Date:  2018-09-20       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.